USFDA inspection at Ahmedabad injectable plant closed with NIL observations

Regulatory & Legal View source PDF Explain this filing

ZYDUSLIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.1%Reaction day

₹901.35

prior close

₹905.80

announcement price

After-mkt

timing

Nifty 100market · index membership as recorded later (tracked since Jun 2026)+0.5%-0.4% vs market

Pharmaceuticals peers, median of 156sector-0.2%+0.3% vs sector

On the reaction day the stock moved 0.4 pts less than Nifty 100 and 0.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.5

10m

-0.6

15m

-0.6

30m

-0.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.1+0.5-0.4-0.2+0.3

Next day

+0.4+1.0-0.6-0.3+0.8

+0.6+0.1+0.5-1.1+1.7

+1.9+0.4+1.5-1.0+2.9

+4.1+0.5+3.6-0.4+4.5

+2.4-0.7+3.1-1.7+4.0

-0.5-3.7+3.2-5.3+4.8

15d

-1.8-7.8+6.0-6.2+4.5

-1.2-8.9+7.7-5.3+4.1

+3.7-3.2+6.9+1.7+2.1

+15.4-5.7+21.2+5.8+9.6

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 156Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Zydus Lifesciences announced that the US FDA conducted a Pre Approval Inspection (PAI) for Injectable Medical Devices at the company's Unit 9 facility at Zydus Biotech Park, Changodar, Ahmedabad. The inspection ran from 16 to 19 February 2026 and closed with NIL observations, meaning no issues or deficiencies were noted by the regulator.

Likely market impact

Positive outcome. A clean USFDA inspection supports timely product approvals and signals strong compliance at the injectable plant, reassuring investors.